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Clear cell renal cell carcinoma 
Surgery 
A B S T R A C T   
Purpose: The main aim was to map serum levels of IL-1/IL-6 family cytokines and relevant receptors from serum 
samples taken across treatment in patients with Renal Cell Carcinoma (RCC). Additionally, we explored the 
possible interactions between these measurements, immunohistochemistry and intratumoral blood flow. 
Methods: We included 40 patients undergoing open surgery for renal tumors. Blood samples were collected 
before, during (taken simultaneously from a peripheral site and the renal vein (RV) before clamping) and after 
surgery. Samples were analyzed for IL-6, IL-27, IL-31, OSM, TNF-α, serum (s)-gp130, s-IL-6Rα, s-IL-33R, IL-1Rα 
and VEGF. All 35 RCC tumors were histologically subtyped as clear cell (CCRCC), papillary or chromophobe. 
Immunohistochemistry for the CCRCC group included expression of IL-6/IL-6R. Intratumoral blood flow was 
determined by calculating intratumoral contrast enhancement on preoperative computerized tomography (CT) 
imaging. 
Results: In the CCRCC patients, the intraoperative RV concentration of IL-6 was significantly higher than in both 
the preoperative and postoperative samples (p = 0.005 and p = 0.032, respectively). Furthermore, the intra-
operative ratio showed significantly higher levels of IL-6 in the RV than in the simultaneously drawn peripheral 
sample. Immunohistochemistry showed general expression of IL-6 (23/24) in both tumor cells and the vascu-
lature (20/23). Moreover, s-IL-6R was expressed in tumor cells in 23/24 studied patients. Increased blood flow in 
the CCRCC tumors predicted increased IL-6 levels in the RV (p < 0.001). The other cytokines and receptors 
showed an overall stability across the measurements. However, the intraoperative ratios of IL-33R and gp130 
showed significantly higher levels in the RV. 
Conclusion: Serum levels of IL-6 increased during surgery. Intraoperative IL-6 and s-IL-33R values were higher in 
the RV compared to the periphery, suggesting secretion from the tumor or tumor microenvironment itself. 
Supportive of this is an almost general expression of IL-6/s-IL-6R in tumor cells and IL-6 in vasculature in the 
tumor microenvironment. Other studied cytokines/receptors were remarkably stable across all measurements.   
1. Introduction 
Renal cell carcinoma (RCC) is a complex disease with substantial 
mortality [1] where pathological tumors (pT)-stage and histological 
grade are the best studied prognostic markers [2]. Even though the 
treatment has improved, curative RCC treatment is still based mainly on 
surgery [3]. Therefore, there is an urgent need to learn more about the 
biology of the RCC in order to improve and extend treatment options. 
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Much has been learned from the study of the RCC cells from biopsies 
and RCC cell lines. Von Hippel-Lindau’s research with genomic muta-
tions generating RCC tumors represents one of the crucial breakthroughs 
in this area [4]. However, as with most other carcinomas [5], RCCs 
primarily originate from somatic mutations, i.e. proximal tubule cells 
turn malignant with subsequently broken growth regulation [5]. The 
roles of inflammation in cancer vary, but may be extensive [6]. The 
presence of inflammation may stimulate cancer cells to escape apoptosis 
and grow uncontrollably, which allows the cancer cells to disseminate 
and deregulate tumor surveillance [6]. RCC represents one of the major 
inflammatory related carcinomas [7]. 
What often kills recurrent RCC patients is disseminated disease [2]. 
Malignant tumors may seed tumor cells into the blood or lymphatic 
circulation and give rise to distant metastasis [8]. Such tumor cells need 
supportive cells in order to build metastases. The latter includes fibro-
blasts, vascular, and inflammatory cells [8]. A limiting step of metastasis 
formation is the tumor cell’s ability to form such aggregates [9]. 
High levels of many inflammatory cytokines measured from blood at 
diagnosis, points to subsequent RCC metastasis formation [10]. The best 
evidence is found regarding interleukin (IL)-6, but other cytokines in the 
IL-6 and IL-1 families and associated receptors show the same ability 
[11]. IL-6 has also been shown to promote tumor proliferation, metas-
tases and cachexia [12]. IL-6 is synthesized by monocytes, macrophages, 
Th2 cells, B cells, astrocytes, endothelial cells, adipocytes and some 
tumor cells [12]. IL-6 has two different ways to initiate cell signaling; 
classic and trans signaling. IL-6 stimulates classic signaling, whereby it 
binds to a membrane-bound IL-6 receptor expressed in only a few cells 
(hepatocytes, neutrophils, monocytes, macrophages and some lympho-
cytes) [13]. The alternative IL- 6 trans-signaling is more generalized, and 
binds membrane signal transducing receptor glycoprotein 130 kDa 
(gp130) through the sIL-6R. Thus, in short, IL-6 promotes general 
inflammation [14]. Soluble gp130 can bind to sIL-6 and prevent IL-6 
binding to sIL-6R. As a result, it inhibits trans signaling and functions 
as a buffer [12]. S-gp130 is present in high serum concentrations and 
under normal circumstances, the concentration is double that of IL-6 
[13]. All cytokines in the IL-6 family utilize glycoprotein 130 (gp130) 
for cellular membrane signal transduction [15]. Therefore, knowing 
how IL-6Ra and gp-130 change, will help better our understanding of the 
mechanisms behind the consequences of a changed s-IL-6. 
Further members of the family include IL-11, IL-27, IL-31, ciliary 
neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin 
M (OSM) and cardiotrophin-like cytokine factor 1 (CLC) [16]. Both IL-6 
and other IL-6 family cytokines (IL-27) and receptors (s-gp130) have 
also been predictive for RCC survival [11]. IL-1 family members also 
play a crucial role in innate immunity [17]. IL-33 is an IL-1 family 
member, and soluble ST2/IL-1 receptor ligand 1 is an IL-33 receptor 
[18]. s-IL-33R is a biomarker in cardiovascular disease and has a critical 
role in e.g., lung, liver and head and neck squamous cancer [19]. 
However, it has been shown that high serum levels of s-IL-33R at diag-
nosis predicts worse prognosis among RCC patients [20]. However, it is 
noteworthy that most of these studies rely on only one sample from each 
patient. An important question is therefore to what extent the cytokine 
concentrations vary depending on whether they are sampled before, 
during and/or after removal of the tumor. Therefore, the first aim of this 
study was to determine if there is a variation in plasma concentrations of 
members of IL-6, IL-1 family and VEGF cytokines as well as certain re-
ceptors when comparing measurements before, during and following 
RCC surgery. 
Furthermore, in a previous study among clear cell RCC (CCRCC) 
patients [11], we demonstrated that patients with high IL-6 had a worse 
prognosis and a high expression of IL-6 on immunohistochemistry. 
Therefore, it is of interest to extend such studies to a more general 
CCRCC population. The second aim of this study is to explore whether 
there is a difference in immunohistochemistry between the CCRCC pa-
tients with high and low levels of IL-6 preoperatively. 
Our previous study has demonstrated that IL-6 is found in 
endothelial cells within the CCRCC tumor [11]. Therefore, this raises the 
question whether different levels of vascularization and subsequently 
blood flow through the tumor are associated with measurable changes in 
cytokine levels. Accordingly, the third aim of the study was to use 
contrast enhancement (CE) on CT imaging as a proxy for blood flow in 
order to investigate whether there exists an association between flow 
through RCC tumors, immunohistochemistry and serum levels of in-
flammatory related cytokines. 
2. Material and Methods 
2.1. Inclusion and data collection 
Patients with renal tumors planned for open surgery with partial or 
radical nephrectomy between April 2018 and June 2019 at Haukeland 
University Hospital (Bergen, Norway) were invited to participate in this 
prospective study. All patients followed standardized diagnostic work- 
up of our institution, which included routine blood tests and chest-CT, 
in addition to abdominal imaging. Pre-treatment image-guided tumor 
biopsies were taken when indicated (19 of 40 patients). Following a 
complete diagnostic evaluation, all these patients were given a recom-
mendation for surgical treatment by the weekly multidisciplinary team 
(MDT) meeting. 
All data collected for the study, including hemoglobin, C-reactive 
protein (CRP), comorbidities, American Society of Anesthesiologists 
(ASA) score and Eastern Cooperative Oncology Group-Performance 
Status (ECOG-PS) were stored in an electronic case report form. The 
Regional Committee for Medical Research Ethics in Western Norway 
approved the study (Approval No. 2017/1757). All patients signed an 
informed consent form for this study. 
2.2. Cytokine sampling and measurements 
Preoperative blood samples were collected from a peripheral vein on 
the morning of surgery (Blood Sample-1: BS-1). During surgery, a second 
sample (BS-2) was taken from the renal vein (RV) as early as feasibly 
possible. This took place before major dissection of the kidney and 
before clamping. Simultaneously, another sample was collected from a 
peripheral vein in the arm (BS-3). The last sample (BS-4) was collected at 
the first post treatment assessment (4–6 weeks after surgery). For all 
samples, the blood was allowed to clot at room temperature before 
undergoing 15 min of centrifugation at 1000g. It was then stored at – 
80 ◦C. The kit used was Quantikine ® High Sensitivity ELISA - Human IL- 
6 by R&D systems, a bi-techno brand. In this method, a monoclonal 
antibody, specific for human IL-6, is pre-coated on a microplate. IL-6 in 
the samples is bound by the immobilized antibody. The samples are then 
washed four times with Wash buffer. After that, 200 µL Human IL-6 HS 
Conjugate is added to each well and incubated for one hour at room 
temperature. Then washing is repeated before 200 µL of Streptavidin 
Polymer-HRP (1X) is added to each well. The samples are then incubated 
for 30 min at room temperature. Washing is repeated before adding 200 
µL of Substrate Solution to each well and incubating for 30 min. Finally, 
50 µL of Stop Solution is added to each well and the color should change 
from blue to yellow. If it turns green or the colors do not seem uniform, 
the individual must mix it more thoroughly by tapping gently on the 
plate. 
TNF-a, s-IL-33R and VEGF were detected using the Luminex 
immune-bead technology and a high-sensitivity kit (Invitrogen/Bio-
source, Carlsbad, CA, USA). Antibody-coupled beads were incubated 
with serum and incubated with a biotinylated detection antibody, before 
finally being incubated with streptavidin–phycoerythrin. Samples were 
then read by the Luminex’s laser-based fluorescent analytical test in-
strument Luminex® 100™ (Luminex Corporation Austin, TX, USA). 
Gp130, IL-27, IL-31, IL-6Rα, and OSM, measured with the same method: 
Human Premixed Multi-Analyte Kit from R&D system, and the latter by 
the use of the Milliplex map kit Human Pituitary Magnetic Bead Panel 1 
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(Millipore, Sigma-Aldrich, Oslo, Norway). 2.3. Histopathological and immunohistological assessment 
An experienced uropathologist (LB) reclassified all tumors using 
hematoxylin and eosin-stained (H&E) xsections. All tumors were staged 
Fig. 1. CT-scan on the left and macroscopic presentation on the right of a patient treated with nephrectomy for a 12 cm (pT2b) tumor in the lower pole of right 
kidney, PADUA-score 13. Histopathological examination confirmed clear-cell RCC with ISUP nuclear grade 2. The arrows indicate the characteristic yellow cut 
surface that is the macroscopic hallmark of such a tumor. 
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according to the 2009 TNM classification system [21], subtyped into 
clear-cell (CCRCC), papillary (PRCC) or chromophobe (CHRCC) and 
graded according to International Society of Urological Pathology 
(ISUP) criteria [22,23]. Presence of necrosis and sarcomatoid compo-
nents was registered. Each patient was allocated to a 3-tier risk group 
according to their Leibovich score [24]. Fig. 1 shows an example of 
tumor staging. 
During the re-examination, one representative block was selected 
from each slide set. The selected slide contained both tumor tissue 
corresponding to the tumor nuclear grade and an area bordering on and 
comprising kidney parenchyma (interphase zone). Immunohistochem-
istry was performed using the automated benchmark ultra-system 
(Ventana-Diagnostics Roche). Four-micrometer sections from the 
formalin-fixed paraffin embedded (FFPE) tissue blocks were deparaffi-
nized and rehydrated, while antigen retrieval was performed by condi-
tioning the cells in a TRIS-based buffer (CC1, Ventana) and heating 
accordingly. After endogenous peroxidase blocking, the slides were 
incubated with the primary antibodies. Detection was performed by 
using OptiView® (OV) and UltraView ® (UV) DAB detection kits 
(Ventana Medical Systems), with Hematoxylin used as a counterstain. 
Human spleen and lymph node sections were used as positive controls, 
while for negative controls, primary antibodies were omitted (Supple-
mentary Table 1). 
The whole tumor area in the slide was examined and the subjective 
impression of density and number of positive cells were scored semi- 
quantitatively and subjectively. The proportion of IL-6 and IL6R- 
positive tumor cells were scored as “no positive tumor cells” (0), “less 
than 10% positive tumor cells “(±0.5)”, “10% positive tumor cells” 
(1+), “10–50% positive tumor cells” (2+), or “more than 50% positive 
tumor cells” (3+). For CD3, CD68 and FOXP3, 1+ means slight and 
scattered infiltration, 2+ moderate infiltration and 3+ the dense infil-
tration of positive cells in more than 50% of the area. 
From a previously published study from our group [11], we retrieved 
immunohistochemistry (IHC)-data from CCRCC patients (n = 25) sam-
ples with high preoperative IL-6 levels (≥8 pg/ml). All but one in the 
present study had low preoperative IL-6 values (IL-6 < 8 pg/ml). Thus, 
for comparison of IHC findings between patients with low and high 
values of IL-6, we analysed two groups; low (IL-6 < 8 pg/ml); n = 24 and 
high (IL-6 ≥ 8 pg/ml); n = 26. 
2.4. Imaging assessment 
The majority of CCRCC patients (22 of 25) were investigated using a 
CT protocol which consisted of an unenhanced acquisition, an early 
arterial enhancement phase (Bolus-tracking 150 HU in Aorta + 15 sec), a 
nephrogram phase (+100 sec), and an excretory phase (10 min). The 
tumor complexity was scored with a PADUA score [25] by an uro- 
radiologist (LAR). For the remaining three patients, unenhanced ac-
quisitions were not available. The attenuation of lesions was measured 
by identifying the most enhancing homogenous area of the tumor. 
Further, the region of interest (ROI) within the homogenous area was 
maximized to get more reliable enhancement measures. The CE was split 
into four groups (Group 1: <20 HU, Group 2: 20–80 HU, Group 3: 
81–149, and Group 4: ≥150). A pilot of 5 cases, not a part of this study, 
was performed to harmonize the measurement of CE method between 
the observers (GG and KMH). 
2.5. Statistical analysis 
Descriptive analyses were performed for the patients and tumor 
characteristics. Given the data is not distributed normally, the non- 
parametric Wilcoxon test with Bonferroni correction was employed to 
compare paired samples and multiple measurement. The correlation was 
analyzed using Pearson. Mann-Whitney U test was used for comparison 
of IHC between two groups. Kappa analyses were used for interobserver 
correlations. Kappa values should be interpreted as follows: 0–0.20 as 
none to slight, 0.21–0.40 as fair, 0.41– 0.60 as moderate, 0.61–0.80 as 
substantial, and 0.81–1.00 as almost perfect agreement. 
To create values for tumor contrast enhancement (ΔCE) for all 
CCRCC tumors, we assigned the median value for the three unenhanced 
acquisitions. Furthermore, we used the median value of preoperative IL- 
6 in three cases where preoperative measurements were unavailable due 
to hemolysis of the sample. To predict IL-6 increase in the RV, we uti-
lized general linear regression modeling. 
A p-value of less than 0.05 was considered statistically significant. 
Statistical calculations were performed using the IBM® SPSS® Statistics 
software (Release 26.0). 
3. Results 
3.1. Tumor and patientś characteristics 
Most patients had confirmed RCC (n = 35) and of these 25 had 
CCRCC, five had PRCC and five had CHRCC histology. Three patients 
had benign tumors and two patients had sarcomas. Partial nephrectomy 
was performed in 25 of 40 patients (62.5%), whereas a radical ne-
phrectomy was performed in the remaining patients. 
Overall, the mean size of the tumor on preoperative imaging was 5.2 
cm (IQR 2.5–6.4) and the complexity of the tumors, as defined by 
PADUA-score, revealed a median value of 9 (IQR 8–11). Most of the 
patients had posterior tumors (68%). The overall male:female ratio was 
4.7:1. Furthermore, 57% of the patients were in ASA-class 1–2 and 95% 
had performance status 0–1. 
Table 1 and Table 2 shows patient and tumor related characteristics 
for the different histological types of RCC, respectively. Patients with 
PRCC were non-significantly older, while the contrast enhancement was 
higher in the CCRCC compared to the other RCC types (p < 0.001). 
Table 1 
Demographic and clinical characteristics of the 35 patients with renal cell 
carcinoma.   
Clear Cell RCC 
(n = 25) 
Papillary RCC 
(n = 5) 
Chromophobe RCC 
(n = 5) 
Age (years) (Mean, 
Median (IQR)) 
63, 65 (57–74) 72, 72 (70–75) 62, 66 (48–74)  
Gender (n, (%))     
Males 24 (96) 3 (60) 1 (20)  
Females 1 (4) 2 (40) 4 (80)  
ASA-Classa (n, (%))     
1–2 13 (52) 0 4 (80)  
3–4 12 (48) 5 (100) 1 (20)  
ECOG-PSb 0–1 
present (n, (%))     
0–1 23 (92) 5 (100) 5 (100)  




79, 85 (73–93) 75, 76 (59–90) 92, 99 (75–105)  
Operative method (n, 
(%))     
Partial 
nephrectomy 
14 (56) 3 (60) 4 (80)  
Radical 
nephrectomy 
11 (44) 2 (40) 1 (20) 
Data for 5 patients with other histopathological entities (sarcomas (n = 2) and 
benign lesions (n = 3)) are not presented. 
a ASA- American Society of Anesthesiologists (ASA) score. 
b ECOG-PS- Eastern Collabarotive Oncology Group Performance Status. 
c GFR-Glomerular filtration rate calculated using CKD-EPI Creatinine Equa-
tion 2009, IQR-Interquartile range, RCC- Renal cell Carcinoma. 
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3.2. Cytokine levels 
3.2.1. Variability in cytokine concentration across sampling 
Fig. 2 shows the measurements of cytokines across all samples. For 
patients with CCRCC the IL-6 values in the RV (BS-2) were significantly 
higher than the samples taken preoperatively (BS-1) (p = 0.005 and at 
postoperative control (BS-4) (p = 0.032). The preoperative samples (BS- 
1) were not significantly different from the postoperative control sam-
ples (BS-4) (p = 1.0) (Fig. 2). The median concentration of IL-6 in the RV 
was 1.97 (IQR: 1.01–37) times higher than in the preoperative samples 
(BS-2/BS-1). For the CCRCC patients, during surgery, the mean ratio 
between RV and peripheral IL-6 levels (BS-2/BS-3) with confidence in-
tervals, was significantly higher than the expected ratio of 1 (Fig. 3a). 
Tumor size did not affect measured concentrations of IL-6 in any of the 
samples (data not shown). 
Similar analyses for IL-27, IL-31, OSM, TNFα, or VEGF in CCRCC 
patients did not identify any significant changes in the measured sam-
ples (Fig. 3a). 
There were no significant differences in cytokine levels between 
CCRCC and PRCC/ CHRCC. 
3.2.2. Stability of IL-1 and IL-6 family receptors across sampling 
Fig. 4 shows all the measurements for the receptors IL-33R, gp130, 
IL-1Rα and IL-6Rα in the CCRCC group. Despite an overall impression of 
stability, there are a few differences, which reached statistical signifi-
cance. For IL-33R, there was a significant difference intraoperatively 
(BS-2 vs. BS-3, p = 0.041). For gp130, the intraoperative peripheral BS-3 
sample was significantly lower than both the sample taken pre- and 
postoperatively (BS-1 and BS-4, p = 0.023 and p = 0.037, respectively). 
IL-1Rα showed higher values in the RV compared to preoperatively (BS- 
2 vs. BS-1, p = 0.008). IL-6Rα demonstrated no significant differences 
across the measurements. 
For the CCRCC patients, during surgery, the mean ratio between RV 
and peripheral IL-33R and gp130 levels (BS-2/BS-3) with confidence 
intervals, were significantly different and higher than the expected ratio 
of 1 (Fig. 3b). 
PRCC patients demonstrated significantly higher levels of IL-6Rα in 
both BS-1 and BS-2 (Supplementary Fig. 1). Otherwise, there were no 
significant differences in receptor levels between CCRCC and PRCC/ 
CHRCC. 
3.2.3. Correlation between cytokines/receptors across measurements 
By correlating all cytokines and receptors, the best correlation was 
found for the individual cytokine / receptor (intraclass). IL-6 showed the 
least overall intraclass correlation, while IL-27, OSM, IL-33R and VEGF 
demonstrated the highest. Between cytokines / receptors, the highest 
overall correlation was seen between different measurements of IL-33R 
and VEGF, IL-6Rα and OSM, IL-1Ra and IL-27 and IL-6Rα and IL-27. 
Supplementary Table 2 demonstrates the correlations for both intra-
class and between cytokines/receptors among CCRCC patients. 
3.3. Immunohistochemistry for CCRCC 
We calculated the levels of CD3, CD68, FoxP3, IL-6 and IL-6R posi-
tive cells in the patients’ tumors and the surrounding tissue (n = 24). 
The density and number of positive cells were scored semi- 
quantitatively. The following number of patients had 10% or more 
expression by immunohistochemistry: CD3 positive tumor lymphocytes 
24/24; CD3 positive lymphocytes in interphase zone 19/23: CD68 pos-
itive cells in tumor 20/24: CD68 positive interphase zone cell 6/23: 
FoxP3 in tumor infiltrating lymphocytes 4/24: FoxP3 in interphase zone 
lymphocytes 3/24. FoxP3 in tumor cells 0/24 (Fig. 5). 
Regarding IL-6, none of the patients showed expression in tumor 
lymphocytes and only one in interphase zone lymphocytes. On the other 
hand, 23/24 were IL-6 positive in tumor cells and 20/23 in the vascu-
lature (Fig. 5). Expression of IL-6R in tumor cells was seen in 23/24 of 
the studied patients (Table 3). 
Comparing CCRCC patients with low IL-6 and those with high, there 
was a difference between them concerning expression of IL-6 in tumor 
cells (p < 0.001). Furthermore, there is a much higher expression of IL- 
6R in tumor cells (p < 0.001) and FoxP3 in tumor lymphocytes in those 
with higher pre-operative IL-6 (p = 0.039). There was no difference in 
expression of CD3 nor CD68 in lymphocytes between those two groups 
(data not shown). 
Table 2 
Histopathological and radiological characteristics of the 35 patients with renal cell carcinoma.   
Clear Cell RCC (n = 25) Papillary RCC (n = 5) Chromophobe RCC (n = 5) 
Tumor size (cm)(Mean, Median (IQR)) 4.3, 3.3 (2.4–5.3) 7.6, 3.4 (2.9–14.5) 5.0, 3.3 (2.5–8.5)  
ISUP-gradea (n, (%))     
1 4 (16) 0 n/a  
2 19 (76) 5 (100)   
3 2 (8) 0   
4 0 0   
Sarcomatoid component present (n, (%)) 0 0 1 (20)  
Necrosis present (n, (%)) 1 (4) 1 (20)   
pT-stage (n, (%))     
1a 17 (68) 3 (60) 3 (60)  
1b 4 (16) 0 1 (20)  
2a 1 (4) 1 (20) 1 (20)  
2b 2 (8) 1 (20) 0  
3a 1 (4) 0 0  
PADUAb-Score (median (IQR)) 10 (7.5–11.5) 8 (7–11) 9 (9–11)  
Contrast enhancement (HU) (Mean, Median (IQR)) 111, 106 (70–131) 44, 42 (32–58) 86, 64 (56–127)  
Leibovichc-score (median (IQR)) 0 (0–2) 2 (1–4.5) 0 (0–3.5) 
HU-Hounsfield Units, IQR-Interquartile range, RCC- Renal cell Carcinoma, pT-Stage – Pathological T-stage according to UICC 2010 version of the TNM classification. 
Data for 5 patients with other histopathological entities (sarcomas (n = 2) and benign lesions (n = 3)) are not presented, n/a – ISUP nuclear grading is not applicable to 
chromophobe RCC 
a ISUP-The International Society of Urological Pathology (ISUP) nuclear grade. 
b PADUA-Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) Classification of Renal Tumours. 
c Leibovich score-Prognostic score that is based on T stage, size, lymph node status, nuclear grade and presence of tumor necrosis (Higher score gives worse prognosis 
(0–11)). 
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FoxP3 in the interphase zone lymphocytes correlated to s-IL-6 
intraoperatively (BS-2 and BS-3, p = 0.01 and p = 0.042, respectively). 
s-IL-6 preoperatively (BS-1) and at control (BS-4) correlated with IL-6 
tumor lymphocytes, p = 0.011, and p = 0.034, respectively. Preopera-
tively. IL-6 (BS-1) correlates with IL-6 in tumor cells (p = 0.018) and IL- 
6R in tumor cells (p = 0.013). Stage and size correlate to IL-6R in tumor 
cells (p = 0.032 and p = 0.028, respectively). There was no other 
correlation between IHC and known histopathological risk factors. 
3.4. Interactions between contrast enhancement, IL-6 measurements, and 
immunohistochemistry within CCRCC 
The interrater reliability for CE on CT-scans was high (k = 0.61). For 
the following analyses, we used the result from one reader (GG). Data 
Fig. 2. The figure shows the all the values with boxplots for six cytokines measured in blood samples (BS) preoperatively (BS-1), intraoperatively and simultaneously 
from the renal vein (BS-2) and peripherally (BS-3) and at postoperative control after 4–6 weeks (BS-4). The intraoperative measurement from the renal vein (BS-2) of 
IL-6 is significantly higher than in the preoperative (BS-1) and postoperative (BS-4) samples (p = 0.005 and p = 0.032, respectively). For the other cytokines there are 
no significant differences. 
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from the other reader (KMH) showed similar results (data not shown). 
Comparing CE and the IL-6 values, there was a significant correlation 
with both the IL-6 samples taken during surgery (BS-2 and BS-3 with a p- 
value < 0.01 and p < 0.05, respectively). No significant correlation was 
found between IL-6 changes and IHC, nor between IHC and CE. In a 
linear regression model, only higher CE remained an independent pre-
dictor of increased levels of IL-6 in the RV (p < 0.001) with an explained 
variance (r2) of 0.595. 
Fig. 3. The figures shows the mean of the intraoperative ratios (renal vein (BS-2)/peripherally (BS-3) with confidence intervals for A) cytokines and B) receptors. The 
red line represent the expected BS-2 /BS-3 ratio given an even distribution in the body. IL-6, IL-33R and gp130 have confidence intervals that does not include 1. 
Fig. 4. The figure shows the all the values with boxplots for four receptors measured in blood samples (BS) preoperatively (BS-1), intraoperatively and simulta-
neously from the renal vein (BS-2) and peripherally (BS-3) and at postoperative control after 4–6 weeks (BS-4). The intraoperative measurement from the renal vein 
(BS-2) of gp130 is significantly lower than in the preoperative (BS-1) and postoperative (BS-4) samples (p = 0.023 and p = 0.037, respectively). IL-1Rα showed 
increased values in the renal vein compared to preoperatively (BS-2 vs. BS-1, p = 0.008). Otherwise, no significant differences were observed. 
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4. Discussion 
There are two main findings in this this small pilot study investi-
gating serum IL-1 - and IL-6 family cytokines and related receptors in 
CCRCC patients before, during and after surgery. Firstly, the stability of 
the majority of cytokines and receptors and secondly, the observed in-
crease in IL-6 intraoperatively. 
The remarkably constant level of the measured cytokines and cyto-
kine receptors from the pre-treatment samples to the six week post- 
treatment samples was unexpected, but adds substantial validity to 
one-sample studies regarding (RCC) cancer. Scientific understanding of 
the half-life of human cytokines in blood is lacking. The elimination half- 
life for IL-6 is approximately 15 h and 12 h for rats and mice, respec-
tively [26]. In humans, the elimination half-life is approximately 13 h 
[27]. To our knowledge, there are no previous studies investigating the 
elimination half-life of IL-6 in RCC patients. This study supports a 
relatively long elimination half-life (5–15 h) in humans because of the 
measured stability of the cytokine concentrations. Furthermore, the 
stability of many of the different cytokine concentrations throughout 
treatment suggests a “thermostat” that regulates cytokine concentra-
tions and the liver is a possible candidate for this [28]. 
Our results have demonstrated that serum concentration of IL-6 
increased during surgery. IL-6 is a cytokine, which is produced by 
many cells as a response to stimuli [12]. Physical exercise, such as long- 
distance walking, has been shown to increase IL-6 up to 10 times over 
24 h [29]. Thus, it is likely that a physical trauma like open surgery may 
increase the general level of IL-6 both during surgery and immediately 
afterwards. We found a 3:1 ratio between IL-6 samples collected from 
the RV compared to preoperatively for all patients and 2:1 for CCRCC. 
This is lower than the 10:1 ratio that Blay et al. previously published in a 
series of three patients [30]. However, based on our intraoperative 
measurements, which show a significant difference between the samples 
from the renal vein and peripherally, extrarenal production of IL-6 is 
probably not the whole explanation for this increase. 
The concentrations of s-IL-6Rα and s-gp130 measured in this study 
changed minimally. This supports that the hypothesis that measured IL- 
6 concentrations are functionally relevant given both IL-6 concentra-
tions acting on the membrane bound IL-6 receptor and the complex of 
IL-6/sIL-6Rα stimulated the relevant cell more. This is further supported 
by minimal change in s-gp130 concentrations. The changed IL-6 levels 
appear therefore to be physiologically relevant. 
Based on the supporting results in this study, we hypothesize that a 
substantial part of the increase in IL-6 is due to production within the 
tumor cells and/or from the tumor vasculature. The present IHC data 
demonstrates the general expression of IL-6/s-IL-6R in tumor cells and 
IL-6 in vasculature as evidence of tumor IL-6 synthesis which confirms 
earlier results [11]. When comparing patients with high versus low 
preoperative serum levels of IL-6, the former were shown to have both 
higher density of IL-6 and higher expression of IL-6R in tumor cells, 
which supports the theory that the tumor as a source for circulating 
serum IL-6. Moreover, the CE is an indicator of vascularization and 
blood flow through the tumor. The larger increase in IL-6 values in the 
RV among those with higher tumor CE, also indicates that RCC tumors 
are associated with IL-6 production. Overall, our results are compliant 
with a hypothesis that RCC tumor cells secrete IL-6 and likely stimulate 
the vascular cells to do the same. 
Previously, we have shown that both IL-6 and IL-27, when measured 
at diagnosis, predicted recurrence and DSS to a similar extent [11]. 
These cytokines share the gp130 receptor, i.e. the β-part of the receptor. 
Regarding these two cytokines, the present study suggests it is not the 
membrane bound gp130 receptor, which is the sole mechanism for the 
survival predictions. Further studies on this are warranted. In the case of 
Fig. 5. Immunohistochemical staining for FOXP3 and IL-6 in clear cell renal cell carcinoma. A) Tumor tissue negative for FOXP3, score 0. B) Arrows pointing at 
FOXP3 positive intramural lymphocytes, score 1 (slight and scattered infiltration). C) Arrow pointing at IL-6 positive medial smooth muscle in an intrarenal artery, 
score 1 (10% positive cells). D) Arrow pointing at IL-6 positive medial smooth muscle cells in intrarenal artery, score 2 (10–50% positive cells). 
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IL-6, we have studied the soluble receptors IL-6Rα and soluble gp130 
levels. The decoy receptor gp130 had decreased concentration versus no 
significant change regarding the trans-activating IL-6Rα. Thus, it is 
supported that both the IL-6 classical- and trans-activation will be 
strengthened through these soluble receptors with increased serum IL-6 
as part of RCC pathophysiology. Regarding the IL-1 family cytokines and 
receptors, we have shown that s-IL-33R concentration were increased in 
the RV. IL-33R is considered a decoy receptor [20]. However, most 
published studies on soluble (decoy) receptors indicate worse cancer 
prognosis with increased such concentrations [20]. This could be 
explained by the cellular turnover of tumors but this needs to be studied 
in more detail. We have shown a considerable presence of T lympho-
cytes, both within the tumor and the interphase. On the other hand, 
fewer lymphocytes were FoxP3 positive, suggesting few T regulatory 
cells. Interestingly, the presence of IL-6R on lymphocytes was more 
abundant with higher IL-6 serum levels suggesting that IL-6 may also 
inhibit T lymphocyte function though classical activation. 
To our knowledge, this is the first study to investigate the levels of IL- 
6- and IL-1-family cytokines in consecutive samples from the same 
cancer patients before, during and after surgery. However, published 
data for comparison and benchmarking is limited. Further limitations 
are that it is a small pilot study with few patients, and there is presence 
of selection bias because only patients undergoing open surgery were 
included. This approach was chosen because it is technically only 
feasible to attain blood from the RV during open surgery. However, the 
surgical trauma by itself might be a confounder that complicates the 
understanding of the changes in IL-6 measurements. Furthermore, in 
this study there is a gender imbalance with more men (4.7:1) than the 
usual 1.5–2:1 ratio known from other cohorts [31]. A strength of this 
study is that each patient serves as their own control. We were able to 
study individual sample values, and therefore examine trends on an 
individual basis at multiple points in time. The intraoperative RV sam-
ples add considerable value to these findings. 
5. Conclusions 
Serum levels of IL-6 increased during surgery. Intraoperative IL-6 
and s-IL-33R values were higher in the RV compared to the periphery, 
which suggests secretion from the tumor or tumor microenvironment 
itself. Supportive of this is an almost general expression of IL-6/s-IL-6R 
in tumor cells and IL-6 in vasculature in the RCC tumor microenviron-
ment. Other studied cytokines were remarkably stable across all the 
measurements. 
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Table 3 
Description of immuno-histochemical analyses patients with CCRCC, staining 
assessment and numbers of patients in each group. Each selected slide contained 
both tumor tissue corresponding to the tumor nuclear grade and an area 
bordering on and comprising kidney parenchyma (interphase zone). The sam-
ples (n = 38) were scored in a semi-quantitative fashion, reviewed by an expert 
in pathology (LB) and further transformed into numeric values for statistical 
analyses according to the following: +++ = 3, ++(+) = 2.5, ++ = 2, +(+) =



























2 2 8 6 4 1 0 
CD68-positive 
cells in tumor 




7 10 4 1 1 0 0 
FoxP3 in tumor 
lymphocytes 




7 13 0 3 0 0 0 
FoxP3 in tumor 
cells 
24 0 0 0 0 0 0 
IL6 in tumor 
lymphocytes 
20 4 0 0 0 0 0 
IL6 in interphase 
zone 
lymphocytes 
18 5 1 0 0 0 0 
IL6 in tumor cells 1 0 4 0 4 0 15 
IL6 in vasculature 1 3 8 0 10 1 1 
IL6 receptor in 
tumor 
lymphocytes2 
0 7 0 0 0 0 0 
IL6R in interphase 
zone 
lymphocytes2 
0 7 0 0 0 0 0 
IL6R in tumor 
cells 
1 0 8 0 3 0 12 
1) n = 23, 2) n = 7. 
The proportion of IL-6 and IL6R-positive tumor cells were scored as “no positive 
tumor cells” (0), “less than 10% positive tumor cells “(±0.5)”, “10% positive 
tumor cells” (1 + ), “10–50% positive tumor cells” (2 + ), or “more than 50% 
positive tumor cells” (3 + ). For CD3, CD68 and FOXP3, 1 + means slight and 
scattered infiltration, 2 + moderate infiltration and 3 + the dense infiltration of 
positive cells in more than 50% of the area. 
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Appendix A. Supplementary material 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.cyto.2021.155586. 
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